Biotechnology company Orchard Therapeutics’ OTL-101 has received a promising innovative medicine designation from the UK Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of adenosine deaminase severe combined immunodeficiency.
Commonly known as ADA-SCID or ‘bubble baby’ disease, adenosine deaminase severe combined immunodeficiency is a rare inherited disorder of the immune system.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
The disease is caused by mutations in the gene encoding for the adenosine deaminase enzyme, which result in a serious deficiency in white blood cells and lead to life-threatening infections.
OTL-101 is developed by Orchard Therapeutics in collaboration with University College London / Great Ormond Street Hospital (UCL / GOSH) and the University of California, Los Angeles (UCLA).
The designation indicates that ADA-SCID is a life-threatening condition with high unmet medical need in spite of the currently available treatment options.
Orchard Therapeutics chief scientific officer and UCL / Institute of Child Health Paediatrics professor Bobby Gaspar said: “We are delighted by the designation of OTL-101 as a promising innovative medicine as it recognises the significant unmet need in ADA-SCID, as well as the major potential clinical benefits of OTL-101 over alternative treatment options.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataOTL-101’s designation as a promising innovative medicine is the first step of a two-step process, under which the Orchard treatment can benefit from the early access to medicine scheme (EAMS).
Orchard Therapeutics Business Operations senior vice-president Nicolas Koebel said: “With this PIM designation we can potentially make OTL-101 available to UK patients sooner under the EAMS."
